Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP751909.RA-LyFaBpnBWCp2Jr8qfPtTecV_Bncdrtfrs6rK8oKBtA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP751909.RA-LyFaBpnBWCp2Jr8qfPtTecV_Bncdrtfrs6rK8oKBtA130_assertion type Assertion NP751909.RA-LyFaBpnBWCp2Jr8qfPtTecV_Bncdrtfrs6rK8oKBtA130_head.
- NP751909.RA-LyFaBpnBWCp2Jr8qfPtTecV_Bncdrtfrs6rK8oKBtA130_assertion description "[We describe treatment of a refractory, progressive Li-Fraumeni syndrome embryonal carcinoma with a p53 therapy (Advexin) targeted to the underlying molecular defect of this syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP751909.RA-LyFaBpnBWCp2Jr8qfPtTecV_Bncdrtfrs6rK8oKBtA130_provenance.
- NP751909.RA-LyFaBpnBWCp2Jr8qfPtTecV_Bncdrtfrs6rK8oKBtA130_assertion evidence source_evidence_literature NP751909.RA-LyFaBpnBWCp2Jr8qfPtTecV_Bncdrtfrs6rK8oKBtA130_provenance.
- NP751909.RA-LyFaBpnBWCp2Jr8qfPtTecV_Bncdrtfrs6rK8oKBtA130_assertion SIO_000772 17483435 NP751909.RA-LyFaBpnBWCp2Jr8qfPtTecV_Bncdrtfrs6rK8oKBtA130_provenance.
- NP751909.RA-LyFaBpnBWCp2Jr8qfPtTecV_Bncdrtfrs6rK8oKBtA130_assertion wasDerivedFrom befree-20150227 NP751909.RA-LyFaBpnBWCp2Jr8qfPtTecV_Bncdrtfrs6rK8oKBtA130_provenance.
- NP751909.RA-LyFaBpnBWCp2Jr8qfPtTecV_Bncdrtfrs6rK8oKBtA130_assertion wasGeneratedBy ECO_0000203 NP751909.RA-LyFaBpnBWCp2Jr8qfPtTecV_Bncdrtfrs6rK8oKBtA130_provenance.